Clinical Trial

A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

Name: A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis — clinical trial record (NCT06943950)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-17.

Trial Details

NCT Number	NCT06943950
Lead Sponsor	CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions	Moderate to Severe Plaque Psoriasis
Enrollment	500 participants
Start Date	2025-06-01
Primary Completion	2027-04-28 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-04-30